With €30M+ Series B, Danish Bactolife prepares shift from R&D to commercial scale

Copenhagen-based Bactolife has raised more than €30 million in a Series B round to move its Binding Protein technology from development into commercialization, as the company prepares for its first human health product launch in the US in 2026. The round was led by Cross Border Impact Ventures and EIFO, with continued backing from existing investors Novo Holdings and Athos. Founded in Copenhagen, Bactolife develops food-grade Binding Proteins designed to bind and neutralize harmful metabolites in the gut, targeting applications across dietary supplements, functional foods, and animal health. The fresh capital will be used to fund large-scale human studies, scale manufacturing via precision fermentation, and support global market entry, with expansion into Europe and Asia planned after the US launch. Alongside its commercial ambitions, the company says it will allocate resources to make the technology accessible to women and children in low- and middle-income countries, positioning Binding Proteins as both a growth product and a global health intervention.

Founded to address unmet needs in gut health, Bactolife develops Binding Proteins—food-grade functional proteins designed to bind and neutralize undesired metabolites in the gastrointestinal system. The proteins are inspired by camelid immunoglobulins and produced at scale using precision fermentation, allowing them to be integrated into dietary supplements, functional foods and beverages, and animal feed products.

According to the company, the new funding will primarily be used to advance clinical validation through human studies across the US, Europe, Asia, and selected low- and middle-income countries (LMICs). Capital will also be allocated to scaling production capabilities and building commercial partnerships ahead of market entry. Bactolife expects to launch its first Binding Protein products for human health in the US in 2026, followed by expansion into European and Asian markets.

Sebastian Søderberg, CEO of Bactolife, expressed his enthusiasm for the funding’s potential:

“Today’s successful close of our Series B round sets the stage for exciting years ahead as we prepare to launch our innovative products in 2026. This funding will enable us to clinically validate, scale, and commercialize our Binding Proteins, taking Bactolife’s solutions to a broad audience. We are excited to welcome new investors to the Bactolife family and are deeply grateful to our existing investors, whose continued support reflects their confidence in our mission. We are ready to transform gut health with novel Binding Proteins.”

Beyond high-income markets, the company says access remains a core part of its strategy. Bactolife plans to make its technology available to women and children in LMICs, positioning Binding Proteins as a scalable, nutrition-compatible intervention rather than a premium health product limited to developed markets.

Investors say the company sits at the intersection of gut microbiome science, food technology, and global health. By combining clinical evidence with a manufacturing platform designed for scale, Bactolife aims to address both commercial demand in the nutraceutical sector and broader public health challenges linked to gut resilience.

Donna Parr, Managing Partner at Cross Border Impact Ventures, highlighted the broader impact of the investment:

“We are thrilled to lead Bactolife’s Series B. Bactolife’s Binding Proteins have the potential to strengthen gut resilience for mothers and children in low- and middle-income countries by providing a scalable, food-grade solution that can be integrated into everyday nutrition. At the same time, we are excited about the significant growth opportunity across North America, Europe, and Asia where the market opportunity is massive. This investment reflects our conviction that evidence-based technologies can reach massive high-growth markets, inclusive of people who need them most, and we look forward to partnering with Bactolife to accelerate clinical validation, scale manufacturing, and expand equitable access globally.”

With the Series B completed, Bactolife is now entering its transition phase from development-stage company to commercial supplier, as it prepares regulatory, manufacturing, and market readiness activities ahead of its planned 2026 launch.

Click to read more funding news.